Redox regulation of genome stability by effects on gene expression, epigenetic pathways and DNA damage/repair

Redox Biology

Volumn 5, Issue , 2015, Pages 275-289

  Mikhed, Yuliya ^a   Görlach, Agnes ^b   Knaus, Ulla G ^c   Daiber, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

DNA repair; Epigenetics; Gene regulation; Oxidative stress; Redox signaling

Indexed keywords

ANACARDIC ACID; ANTINEOPLASTIC AGENT; AZACITIDINE; CISPLATIN; DECITABINE; DNA; ENTINOSTAT; ENZYME ACTIVATOR; FLUOROURACIL; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; HISTONE H1; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; HYDROGEN PEROXIDE; MESSENGER RNA; MICRORNA; NITRIC OXIDE; PENTAERYTHRITYL TETRANITRATE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SPV 106; TAMOXIFEN; THEOPHYLLINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; ZEBULARINE; BIOLOGICAL MARKER; HISTONE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG RESISTANCE; DRUG TARGETING; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HISTONE MODIFICATION; HUMAN; LOW DRUG DOSE; MAMMAL CELL; MYELODYSPLASTIC SYNDROME; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RNA STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; CHEMISTRY; GENETIC EPIGENESIS; METABOLISM;

BIOMARKERS; DNA DAMAGE; DNA REPAIR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HISTONES; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION;

EID: 84930939459     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.05.008     Document Type: Review

References (202)

1. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993, 362(6422):709-715. http://www.ncbi.nlm.nih.gov/pubmed/8469282, 10.1038/362709a0.
2. Alizadeh E., Orlando T.M., Sanche L. Biomolecular damage induced by ionizing radiation: the direct and indirect effects of low-energy electrons on DNA. Annu. Rev. Phys. Chem. 2015, 66:379-398. http://www.ncbi.nlm.nih.gov/pubmed/25580626, 10.1146/annurev-physchem-040513-103605.
3. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 1993, 90(17):7915-7922. http://www.ncbi.nlm.nih.gov/pubmed/8367443, 10.1073/pnas.90.17.7915.
4. Mehta A., Haber J.E. Sources of DNA double-strand breaks and models of recombinational DNA repair. Cold Spring Harb. Perspect. Biol. 2014, 6(9):a016428. http://www.ncbi.nlm.nih.gov/pubmed/25104768, 10.1101/cshperspect.a016428.
5. Madabhushi R., Pan L., Tsai L.H. DNA damage and its links to neurodegeneration. Neuron 2014, 83(2):266-282. http://www.ncbi.nlm.nih.gov/pubmed/25033177, 10.1016/j.neuron.2014.06.034.
6. Haber J.E. DNA recombination: the replication connection. Trends Biochem. Sci. 1999, 24(7):271-275. http://www.ncbi.nlm.nih.gov/pubmed/10390616, 10.1016/S0968-0004(99)01413-9.
7. Vilenchik M.M., Knudson A.G. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl. Acad. Sci. USA 2003, 100(22):12871-12876. http://www.ncbi.nlm.nih.gov/pubmed/14566050, 10.1073/pnas.2135498100.
8. Cadet J., Douki T., Ravanat J.L. Oxidatively generated damage to cellular DNA by UVB and UVA radiation. Photochem. Photobiol. 2015, 91(1):140-155. http://www.ncbi.nlm.nih.gov/pubmed/25327445, 10.1111/php.12368.
9. Liu R.H., Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat. Res. 1995, 339(2):73-89. http://www.ncbi.nlm.nih.gov/pubmed/7791803, 10.1016/0165-1110(95)90004-7.
10. Guetens G., De Boeck G., Highley M., van Oosterom A.T., de Bruijn E.A. Oxidative DNA damage: biological significance and methods of analysis. Crit. Rev. Clin. Lab. Sci. 2002, 39(4-5):331-457. http://www.ncbi.nlm.nih.gov/pubmed/12385502, 10.1080/10408360290795547.
11. Sharma V., Collins L.B., Clement J.M., Zhang Z., Nakamura J., Swenberg J.A. Molecular dosimetry of endogenous and exogenous O(6)-methyl-dG and N7-methyl-G adducts following low dose [D3]-methylnitrosourea exposures in cultured human cells. Chem. Res. Toxicol. 2014, 27(4):480-482. http://www.ncbi.nlm.nih.gov/pubmed/24628573, 10.1021/tx5000602.
12. Tomaszowski K.H., Aasland D., Margison G.P., Williams E., Pinder S.I., Modesti M., Fuchs R.P., Kaina B. The bacterial alkyltransferase-like (eATL) protein protects mammalian cells against methylating agent-induced toxicity. DNA Repair (Amst.) 2015, 28:14-20. http://www.ncbi.nlm.nih.gov/pubmed/25703834, 10.1016/j.dnarep.2015.01.009.
13. Yousef M.I., Hussien H.M. Cisplatin-induced renal toxicity via tumor necrosis factor-α, interleukin 6, tumor suppressor P53, DNA damage, xanthine oxidase, histological changes, oxidative stress and nitric oxide in rats: protective effect of ginseng. Food Chem. Toxicol. 2015, 78:17-25. http://www.ncbi.nlm.nih.gov/pubmed/25640527, 10.1016/j.fct.2015.01.014.
14. Gederaas O.A., Søgaard C.D., Viset T., Bachke S., Bruheim P., Arum C.J., Otterlei M. Increased anticancer efficacy of intravesical mitomycin C therapy when combined with a PCNA targeting peptide. Transl. Oncol. 2014, 7(6):812-823. http://www.ncbi.nlm.nih.gov/pubmed/25500092, 10.1016/j.tranon.2014.10.005.
15. Montariello D., Troiano A., Di Girolamo D., Beneke S., Calabrò V., Quesada P. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells. Biochem. Pharmacol. 2015, 94(3):212-219. http://www.ncbi.nlm.nih.gov/pubmed/25667043, 10.1016/j.bcp.2015.01.012.
16. Kim Y.J., Wilson D.M. Overview of base excision repair biochemistry. Curr. Mol. Pharmacol. 2012, 5(1):3-13. http://www.ncbi.nlm.nih.gov/pubmed/22122461.
17. Lee D.H., Liu Y., Lee H.W., Xia B., Brice A.R., Park S.H., Balduf H., Dominy B.N., Cao W. A structural determinant in the uracil DNA glycosylase superfamily for the removal of uracil from adenine/uracil base pairs. Nucleic Acids Res. 2015, 43(2):1081-1089. http://www.ncbi.nlm.nih.gov/pubmed/25550433, 10.1093/nar/gku1332.
18. Ba X., Aguilera-Aguirre L., Sur S., Boldogh I. 8-Oxoguanine DNA glycosylase-1-driven DNA base excision repair: role in asthma pathogenesis. Curr. Opin. Allergy Clin. Immunol. 2015, 15(1):89-97. http://www.ncbi.nlm.nih.gov/pubmed/25486379, 10.1097/ACI.0000000000000135.
19. Tarry-Adkins J.L., Martin-Gronert M.S., Fernandez-Twinn D.S., Hargreaves I., Alfaradhi M.Z., Land J.M., Aiken C.E., Ozanne S.E. Poor maternal nutrition followed by accelerated postnatal growth leads to alterations in DNA damage and repair, oxidative and nitrosative stress, and oxidative defense capacity in rat heart. FASEB J. 2013, 27(1):379-390. http://www.ncbi.nlm.nih.gov/pubmed/23024373, 10.1096/fj.12-218685.
20. Hegde M.L., Hegde P.M., Bellot L.J., Mandal S.M., Hazra T.K., Li G.M., Boldogh I., Tomkinson A.E., Mitra S. Prereplicative repair of oxidized bases in the human genome is mediated by NEIL1 DNA glycosylase together with replication proteins. Proc. Natl. Acad. Sci. USA 2013, 110(33):E3090-E3099. http://www.ncbi.nlm.nih.gov/pubmed/23898192, 10.1073/pnas.1304231110.
21. Park J.S., Kim H.L., Kim Y.J., Weon J.I., Sung M.K., Chung H.W., Seo Y.R. Human AP endonuclease 1: a potential marker for the prediction of environmental carcinogenesis risk. Oxid Med. Cell. Longev. 2014, 2014:730301. http://www.ncbi.nlm.nih.gov/pubmed/25243052, 10.1155/2014/730301.
22. Dizdaroglu M. Oxidatively induced DNA damage: mechanisms, repair and disease. Cancer Lett. 2012, 327(1-2):26-47. http://www.ncbi.nlm.nih.gov/pubmed/22293091, 10.1016/j.canlet.2012.01.016.
23. Brenerman B.M., Illuzzi J.L., Wilson D.M. Base excision repair capacity in informing healthspan. Carcinogenesis 2014, 35(12):2643-2652. http://www.ncbi.nlm.nih.gov/pubmed/25355293, 10.1093/carcin/bgu225.
24. Dijk M., Typas D., Mullenders L., Pines A. Insight in the multilevel regulation of NER. Exp. Cell Res. 2014, 329(1):116-123. http://www.ncbi.nlm.nih.gov/pubmed/25128816, 10.1016/j.yexcr.2014.08.010.
25. Ziani S., Nagy Z., Alekseev S., Soutoglou E., Egly J.M., Coin F. Sequential and ordered assembly of a large DNA repair complex on undamaged chromatin. J. Cell Biol. 2014, 206(5):589-598. http://www.ncbi.nlm.nih.gov/pubmed/25154395, 10.1083/jcb.201403096.
26. Kamarthapu V., Nudler E. Rethinking transcription coupled DNA repair. Curr. Opin. Microbiol. 2015, 24:15-20. http://www.ncbi.nlm.nih.gov/pubmed/25596348, 10.1016/j.mib.2014.12.005.
27. Scherly D., Nouspikel T., Corlet J., Ucla C., Bairoch A., Clarkson S.G. Complementation of the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2. Nature 1993, 363(6425):182-185. http://www.ncbi.nlm.nih.gov/pubmed/8483504, 10.1038/363182a0.
28. Muro Y., Sugiura K., Mimori T., Akiyama M. DNA mismatch repair enzymes: genetic defects and autoimmunity. Clin. Chim. Acta 2015, 442:102-109. http://www.ncbi.nlm.nih.gov/pubmed/25619773, 10.1016/j.cca.2015.01.014.
29. Iyer R.R., Pluciennik A., Napierala M., Wells R.D. DNA triplet repeat expansion and mismatch repair. Annu. Rev. Biochem. 2015, 84(1). 10.1146/annurev-biochem-060614-034010.
30. Bak S.T., Sakellariou D., Pena-Diaz J. The dual nature of mismatch repair as antimutator and mutator: for better or for worse. Front. Genet. 2014, 5:287. http://www.ncbi.nlm.nih.gov/pubmed/25191341, 10.3389/fgene.2014.00287.
31. House N.C., Koch M.R., Freudenreich C.H. Chromatin modifications and DNA repair: beyond double-strand breaks. Front. Genet. 2014, 5:296. http://www.ncbi.nlm.nih.gov/pubmed/25250043, 10.3389/fgene.2014.00296.
32. Lemaître C., Soutoglou E. DSB (Im)mobility and DNA repair compartmentalization in mammalian cells. J. Mol. Biol. 2015, 427(3):652-658. http://www.ncbi.nlm.nih.gov/pubmed/25463437, 10.1016/j.jmb.2014.11.014.
33. Grundy G.J., Moulding H.A., Caldecott K.W., Rulten S.L. One ring to bring them all - the role of Ku in mammalian non-homologous end joining. DNA Repair (Amst.) 2014, 17:30-38. http://www.ncbi.nlm.nih.gov/pubmed/24680220, 10.1016/j.dnarep.2014.02.019.
34. Jeggo P.A., Downs J.A. Roles of chromatin remodellers in DNA double strand break repair. Exp. Cell Res. 2014, 329(1):69-77. http://www.ncbi.nlm.nih.gov/pubmed/25278484, 10.1016/j.yexcr.2014.09.023.
35. Chandra V., Bhagyaraj E., Parkesh R., Gupta P. Transcription factors and cognate signalling cascades in the regulation of autophagy. Biol. Rev. 2015, 10.1111/brv.12177.
36. Frasor J., El-Shennawy L., Stender J.D., Kastrati I. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol. Cell. Endocrinol. 2014, http://www.ncbi.nlm.nih.gov/pubmed/25450861, 10.1016/j.mce.2014.09.013.
37. Zhang Z., Zhou S., Jiang X., Wang Y.H., Li F., Wang Y.G., Zheng Y., Cai L. The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome. Rev. Endocr. Metab. Disord. 2015, 16(1):35-45. http://www.ncbi.nlm.nih.gov/pubmed/25540093, 10.1007/s11154-014-9305-9.
38. Vrtačnik P., Ostanek B., Mencej-Bedrač S., Marc J. The many faces of estrogen signaling. Biochem. Med. 2014, 24(3):329-342. http://www.ncbi.nlm.nih.gov/pubmed/25351351, 10.11613/BM.2014.035.
39. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148(3):399-408. http://www.ncbi.nlm.nih.gov/pubmed/22304911, 10.1016/j.cell.2012.01.021.
40. Ariumi Y. Multiple functions of DDX3 RNA helicase in gene regulation, tumorigenesis, and viral infection. Front. Genet. 2014, 5:423. http://www.ncbi.nlm.nih.gov/pubmed/25538732, 10.3389/fgene.2014.00423.
41. Manavathi B., Samanthapudi V.S., Gajulapalli V.N. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front. Cell Dev. Biol. 2014, 2:34.
42. Mothes J., Busse D., Kofahl B., Wolf J. Sources of dynamic variability in NF-κB signal transduction: a mechanistic model. BioEssays 2015, 37(4):452-462. http://www.ncbi.nlm.nih.gov/pubmed/25640005, 10.1002/bies.201400113.
43. Mohamed M.R., McFadden G. NFkB inhibitors: strategies from poxviruses. Cell Cycle 2009, 8(19):3125-3132. http://www.ncbi.nlm.nih.gov/pubmed/19738427, 10.4161/cc.8.19.9683.
44. Hayden M.S., Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26(3):203-234. http://www.ncbi.nlm.nih.gov/pubmed/22302935, 10.1101/gad.183434.111.
45. Schenk H., Klein M., Erdbrügger W., Dröge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc. Natl. Acad. Sci. USA 1994, 91(5):1672-1676. http://www.ncbi.nlm.nih.gov/pubmed/8127864, 10.1073/pnas.91.5.1672.
46. Schreck R., Albermann K., Baeuerle P.A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic. Res. Commun. 1992, 17(4):221-237. http://www.ncbi.nlm.nih.gov/pubmed/1473734, 10.3109/10715769209079515.
47. Meyer M., Schreck R., Baeuerle P.A. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993, 12(5):2005-2015. http://www.ncbi.nlm.nih.gov/pubmed/8491191.
48. Uruno A., Yagishita Y., Yamamoto M. The Keap1-Nrf2 system and diabetes mellitus. Arch. Biochem. Biophys. 2015, 566:76-84. http://www.ncbi.nlm.nih.gov/pubmed/25528168, 10.1016/j.abb.2014.12.012.
49. Bhakkiyalakshmi E., Sireesh D., Rajaguru P., Paulmurugan R., Ramkumar K.M. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes. Pharmacol. Res. 2015, 91:104-114. http://www.ncbi.nlm.nih.gov/pubmed/25447793, 10.1016/j.phrs.2014.10.004.
50. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30(4):393-402. http://www.ncbi.nlm.nih.gov/pubmed/18498744, 10.1016/j.molcel.2008.04.009.
51. Pan Y., Mansfield K.D., Bertozzi C.C., Rudenko V., Chan D.A., Giaccia A.J., Simon M.C. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol. Cell. Biol. 2007, 27(3):912-925. http://www.ncbi.nlm.nih.gov/pubmed/17101781, 10.1128/MCB.01223-06.
52. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., Pouysségur J., Yaniv M., Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004, 118(6):781-794. http://www.ncbi.nlm.nih.gov/pubmed/15369676, 10.1016/j.cell.2004.08.025.
53. Diebold I., Flügel D., Becht S., Belaiba R.S., Bonello S., Hess J., Kietzmann T., Görlach A. The hypoxia-inducible factor-2alpha is stabilized by oxidative stress involving NOX4. Antioxid. Redox Signal. 2010, 13(4):425-436. http://www.ncbi.nlm.nih.gov/pubmed/20039838, 10.1089/ars.2009.3014.
54. Masson N., Singleton R.S., Sekirnik R., Trudgian D.C., Ambrose L.J., Miranda M.X., Tian Y.M., Kessler B.M., Schofield C.J., Ratcliffe P.J. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep. 2012, 13(3):251-257. http://www.ncbi.nlm.nih.gov/pubmed/22310300, 10.1038/embor.2012.9.
55. Sumbayev V.V., Budde A., Zhou J., Brüne B. HIF-1alpha protein as a target for S-nitrosation. FEBS Lett. 2003, 535(1-3):106-112. http://www.ncbi.nlm.nih.gov/pubmed/12560087, 10.1016/S0014-5793(02)03887-5.
56. Chowdhury R., Flashman E., Mecinović J., Kramer H.B., Kessler B.M., Frapart Y.M., Boucher J.L., Clifton I.J., McDonough M.A., Schofield C.J. Studies on the reaction of nitric oxide with the hypoxia-inducible factor prolyl hydroxylase domain 2 (EGLN1). J. Mol. Biol. 2011, 410(2):268-279. http://www.ncbi.nlm.nih.gov/pubmed/21601578, 10.1016/j.jmb.2011.04.075.
57. Daiber A., Schildknecht S., Müller J., Kamuf J., Bachschmid M.M., Ullrich V. Chemical model systems for cellular nitrous(yl)ation reactions. Free Radic. Biol. Med. 2009, 47(4):458-467. http://www.ncbi.nlm.nih.gov/pubmed/19477267, 10.1016/j.freeradbiomed.2009.05.019.
58. Daiber A., Oelze M., Wenzel P., Bollmann F., Pautz A., Kleinert H. Heme oxygenase-1 induction and organic nitrate therapy: beneficial effects on endothelial dysfunction, nitrate tolerance, and vascular oxidative stress. Int. J. Hypertens. 2012, 2012:842632. http://www.ncbi.nlm.nih.gov/pubmed/22506100, 10.1155/2012/842632.
59. De Smet C., Lurquin C., Lethé B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 1999, 19(11):7327-7335. http://www.ncbi.nlm.nih.gov/pubmed/10523621.
60. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16(1):6-21. http://www.ncbi.nlm.nih.gov/pubmed/11782440, 10.1101/gad.947102.
61. Moen E.L., Mariani C.J., Zullow H., Jeff-Eke M., Litwin E., Nikitas J.N., Godley L.A. New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunol. Rev. 2015, 263(1):36-49. http://www.ncbi.nlm.nih.gov/pubmed/25510270, 10.1111/imr.12242.
62. Weissman J., Naidu S., Bjornsson H.T. Abnormalities of the DNA methylation mark and its machinery: an emerging cause of neurologic dysfunction. Semin. Neurol. 2014, 34(3):249-257. http://www.ncbi.nlm.nih.gov/pubmed/25192503, 10.1055/s-0034-1386763.
63. Wan J., Oliver V.F., Wang G., Zhu H., Zack D.J., Merbs S.L., Qian J. Characterization of tissue-specific differential DNA methylation suggests distinct modes of positive and negative gene expression regulation. BMC Genomics 2015, 16:49. http://www.ncbi.nlm.nih.gov/pubmed/25652663, 10.1186/s12864-015-1271-4.
64. Le J.M., Squarize C.H., Castilho R.M. Histone modifications: targeting head and neck cancer stem cells. World J. Stem Cells 2014, 6(5):511-525. http://www.ncbi.nlm.nih.gov/pubmed/25426249, 10.4252/wjsc.v6.i5.511.
65. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705. http://www.ncbi.nlm.nih.gov/pubmed/17320507, 10.1016/j.cell.2007.02.005.
66. Dekker F.J., Haisma H.J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 2009, 14(19-20):942-948. http://www.ncbi.nlm.nih.gov/pubmed/19577000, 10.1016/j.drudis.2009.06.008.
67. Gallinari P., Di Marco S., Jones P., Pallaoro M., Steinkühler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007, 17(3):195-211. http://www.ncbi.nlm.nih.gov/pubmed/17325692, 10.1038/sj.cr.7310149.
68. Di Lorenzo A., Bedford M.T. Histone arginine methylation. FEBS Lett. 2011, 585(13):2024-2031. http://www.ncbi.nlm.nih.gov/pubmed/21074527, 10.1016/j.febslet.2010.11.010.
69. Völkel P., Angrand P.O. The control of histone lysine methylation in epigenetic regulation. Biochimie 2007, 89(1):1-20. http://www.ncbi.nlm.nih.gov/pubmed/16919862, 10.1016/j.biochi.2006.07.009.
70. Mancuso M., Matassa D.S., Conte M., Colella G., Rana G., Fucci L., Piscopo M. H3K4 histone methylation in oral squamous cell carcinoma. Acta Biochim. Pol. 2009, 56(3):405-410. http://www.ncbi.nlm.nih.gov/pubmed/19753335.
71. Rodriguez A., Griffiths-Jones S., Ashurst J.L., Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004, 14(10A):1902-1910. http://www.ncbi.nlm.nih.gov/pubmed/15364901, 10.1101/gr.2722704.
72. Wang J., Gong L., Tan Y., Hui R., Wang Y. Hypertensive epigenetics: from DNA methylation to microRNAs. J. Hum. Hypertens. 2015, 10.1038/jhh.2014.132.
73. Jinek M., Doudna J.A. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009, 457(7228):405-412. http://www.ncbi.nlm.nih.gov/pubmed/19158786, 10.1038/nature07755.
74. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297. http://www.ncbi.nlm.nih.gov/pubmed/14744438, 10.1016/S0092-8674(04)00045-5.
75. Villegas V.E., Zaphiropoulos P.G. Neighboring Gene Regulation by antisense Long non-coding RNAs. Int. J. Mol. Sci. 2015, 16(2):3251-3266. http://www.ncbi.nlm.nih.gov/pubmed/25654223, 10.3390/ijms16023251.
76. Chen A., Chen D., Daiber A., Faraci F., Li H., Rembold C., Laher I. Free radical biology of the cardiovascular system. Clin. Sci. 2012, 123(2):73-91. 10.1042/CS20110562.
77. Yorek M.A. The role of oxidative stress in diabetic vascular and neural disease. Free Radic. Res. 2003, 37(5):471-480. http://www.ncbi.nlm.nih.gov/pubmed/12797466, 10.1080/1071576031000083161.
78. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108(16):1912-1916. http://www.ncbi.nlm.nih.gov/pubmed/14568884, 10.1161/01.CIR.0000093660.86242.BB.
79. Sies H. Oxidative Stress: Oxidants and Antioxidants 1991, Academic Press, London, UK. 10.1113/expphysiol.1997.sp004024.
80. Karbach S., Wenzel P., Waisman A., Munzel T., Daiber A. eNOS uncoupling in cardiovascular diseases - the role of oxidative stress and inflammation. Curr. Pharm. Des. 2014, 20(22):3579-3594. http://www.ncbi.nlm.nih.gov/pubmed/24180381, 10.2174/13816128113196660748.
81. Münzel T., Gori T., Bruno R.M., Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease?. Eur. Heart J. 2010, 31(22):2741-2748. http://www.ncbi.nlm.nih.gov/pubmed/20974801, 10.1093/eurheartj/ehq396.
82. Nezis I.P., Stenmark H. p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxid. Redox Signal. 2012, 17(5):786-793. http://www.ncbi.nlm.nih.gov/pubmed/22074114, 10.1089/ars.2011.4394.
83. Ischiropoulos H., Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J. Clin. Investig. 2003, 111(2):163-169. http://www.ncbi.nlm.nih.gov/pubmed/12531868, 10.1172/JCI17638.
84. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003, 108(17):2034-2040. http://www.ncbi.nlm.nih.gov/pubmed/14581381, 10.1161/01.CIR.0000093661.90582.c4.
85. A. Daiber, M. Oelze, S. Daub, S. Steven, A. Schuff, S. Kroller-Schon, M. Hausding, P. Wenzel, E. Schulz, T. Gori, T. Munzel, Vascular redox signaling, redox switches in endothelial nitric oxide synthase and endothelial dysfunction, in: I. Laher (Ed.), Systems Biology of Free Radicals and Antioxidants, Springer-Verlag, Berlin Heidelberg, 2014, pp. 1177-1211.
86. Gori T., Münzel T. Oxidative stress and endothelial dysfunction: therapeutic implications. Ann. Med. 2011, 43(4):259-272. http://www.ncbi.nlm.nih.gov/pubmed/21284528, 10.3109/07853890.2010.543920.
87. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. J. Am. Med. Assoc. 2007, 297(8):842-857. http://www.ncbi.nlm.nih.gov/pubmed/17327526, 10.1001/jama.297.8.842.
88. Bjelakovic G., Nikolova D., Simonetti R.G., Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004, 364(9441):1219-1228. http://www.ncbi.nlm.nih.gov/pubmed/15464182, 10.1016/S0140-6736(04)17138-9.
89. Lönn M.E., Dennis J.M., Stocker R. Actions of "antioxidants" in the protection against atherosclerosis. Free Radic. Biol. Med. 2012, 53(4):863-884. http://www.ncbi.nlm.nih.gov/pubmed/22664312, 10.1016/j.freeradbiomed.2012.05.027.
90. Rocha M., Apostolova N., Hernandez-Mijares A., Herance R., Victor V.M. Oxidative stress and endothelial dysfunction in cardiovascular disease: mitochondria-targeted therapeutics. Curr. Med. Chem. 2010, 17(32):3827-3841. http://www.ncbi.nlm.nih.gov/pubmed/20858217, 10.2174/092986710793205444.
91. Jazwa A., Cuadrado A. Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr. Drug Targets 2010, 11(12):1517-1531. http://www.ncbi.nlm.nih.gov/pubmed/20704549, 10.2174/1389450111009011517.
92. Wind S., Beuerlein K., Eucker T., Müller H., Scheurer P., Armitage M.E., Ho H., Schmidt H.H., Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 2010, 161(4):885-898. http://www.ncbi.nlm.nih.gov/pubmed/20860666, 10.1111/j.1476-5381.2010.00920.x.
93. Adcock I.M., Cosio B., Tsaprouni L., Barnes P.J., Ito K. Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. Antioxid. Redox Signal. 2005, 7(1-2):144-152. http://www.ncbi.nlm.nih.gov/pubmed/15650403, 10.1089/ars.2005.7.144.
94. Haddad J.J. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal. 2002, 14(11):879-897. http://www.ncbi.nlm.nih.gov/pubmed/12220615, 10.1016/S0898-6568(02)00053-0.
95. Brigelius-Flohé R., Flohé L. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid. Redox Signal. 2011, 15(8):2335-2381. http://www.ncbi.nlm.nih.gov/pubmed/21194351, 10.1089/ars.2010.3534.
96. Hausladen A., Privalle C.T., Keng T., DeAngelo J., Stamler J.S. Nitrosative stress: activation of the transcription factor OxyR. Cell 1996, 86(5):719-729. http://www.ncbi.nlm.nih.gov/pubmed/8797819, 10.1016/S0092-8674(00)80147-6.
97. 2 involves KEAP1 disulfide formation. J. Biol. Chem. 2010, 285(11):8463-8471. http://www.ncbi.nlm.nih.gov/pubmed/20061377, 10.1074/jbc.M109.051714.
98. 2 and diamide. J. Biol. Chem. 1997, 272(12):7908-7914. http://www.ncbi.nlm.nih.gov/pubmed/9065458, 10.1074/jbc.272.12.7908.
99. Dehne N., Brüne B. Sensors, transmitters, and targets in mitochondrial oxygen shortage-a hypoxia-inducible factor relay story. Antioxid. Redox Signal. 2014, 20(2):339-352. http://www.ncbi.nlm.nih.gov/pubmed/22794181, 10.1089/ars.2012.4776.
100. Abdelmohsen K., Kuwano Y., Kim H.H., Gorospe M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol. Chem. 2008, 389(3):243-255. http://www.ncbi.nlm.nih.gov/pubmed/18177264, 10.1515/BC.2008.022.
101. Rodríguez-Pascual F., Redondo-Horcajo M., Magán-Marchal N., Lagares D., Martínez-Ruiz A., Kleinert H., Lamas S. Glyceraldehyde-3-phosphate dehydrogenase regulates endothelin-1 expression by a novel, redox-sensitive mechanism involving mRNA stability. Mol. Cell. Biol. 2008, 28(23):7139-7155. http://www.ncbi.nlm.nih.gov/pubmed/18809573, 10.1128/MCB.01145-08.
102. Klöss S., Srivastava R., Mülsch A. Down-regulation of soluble guanylyl cyclase expression by cyclic AMP is mediated by mRNA-stabilizing protein HuR. Mol. Pharmacol. 2004, 65(6):1440-1451. http://www.ncbi.nlm.nih.gov/pubmed/15155837, 10.1124/mol.65.6.1440.
103. Kuwano Y., Rabinovic A., Srikantan S., Gorospe M., Demple B. Analysis of nitric oxide-stabilized mRNAs in human fibroblasts reveals HuR-dependent heme oxygenase 1 upregulation. Mol. Cell. Biol. 2009, 29(10):2622-2635. http://www.ncbi.nlm.nih.gov/pubmed/19289500, 10.1128/MCB.01495-08.
104. Stoecklin G., Stubbs T., Kedersha N., Wax S., Rigby W.F., Blackwell T.K., Anderson P. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J. 2004, 23(6):1313-1324. http://www.ncbi.nlm.nih.gov/pubmed/15014438, 10.1038/sj.emboj.7600163.
105. Go Y.M., Jones D.P. Redox control systems in the nucleus: mechanisms and functions. Antioxid. Redox Signal. 2010, 13(4):489-509. http://www.ncbi.nlm.nih.gov/pubmed/20210649, 10.1089/ars.2009.3021.
106. Luo M., He H., Kelley M.R., Georgiadis M.M. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid. Redox Signal. 2010, 12(11):1247-1269. http://www.ncbi.nlm.nih.gov/pubmed/19764832, 10.1089/ars.2009.2698.
107. Suthanthiran M., Anderson M.E., Sharma V.K., Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc. Natl. Acad. Sci. USA 1990, 87(9):3343-3347. http://www.ncbi.nlm.nih.gov/pubmed/1970635, 10.1073/pnas.87.9.3343.
108. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid. Redox Signal. 2000, 2(4):811-820. http://www.ncbi.nlm.nih.gov/pubmed/11213485, 10.1089/ars.2000.2.4-811.
109. Lillig C.H., Berndt C., Holmgren A. Glutaredoxin systems. Biochim. Biophys. Acta 2008, 1780(11):1304-1317. http://www.ncbi.nlm.nih.gov/pubmed/18621099, 10.1016/j.bbagen.2008.06.003.
110. Holmgren A., Johansson C., Berndt C., Lönn M.E., Hudemann C., Lillig C.H. Thiol redox control via thioredoxin and glutaredoxin systems. Biochem. Soc. Trans. 2005, 33(6):1375-1377. http://www.ncbi.nlm.nih.gov/pubmed/16246122, 10.1042/BST20051375.
111. Hansen J.M., Zhang H., Jones D.P. Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-kappaB activation, and apoptosis. Toxicol. Sci. Off. J. Soc. Toxicol. 2006, 91:643-650.
112. Yamawaki H., Berk B.C. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr. Opin. Nephrol. Hypertens. 2005, 14(2):149-153. http://www.ncbi.nlm.nih.gov/pubmed/15687841, 10.1097/00041552-200503000-00010.
113. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 1997, 94(8):3633-3638. http://www.ncbi.nlm.nih.gov/pubmed/9108029, 10.1073/pnas.94.8.3633.
114. Xanthoudakis S., Miao G.G., Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. USA 1994, 91(1):23-27. http://www.ncbi.nlm.nih.gov/pubmed/7506414, 10.1073/pnas.91.1.23.
115. Azam S., Jouvet N., Jilani A., Vongsamphanh R., Yang X., Yang S., Ramotar D. Human glyceraldehyde-3-phosphate dehydrogenase plays a direct role in reactivating oxidized forms of the DNA repair enzyme APE1. J. Biol. Chem. 2008, 283(45):30632-30641. http://www.ncbi.nlm.nih.gov/pubmed/18776186, 10.1074/jbc.M801401200.
116. Gaiddon C., Moorthy N.C., Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J. 1999, 18(20):5609-5621. http://www.ncbi.nlm.nih.gov/pubmed/10523305, 10.1093/emboj/18.20.5609.
117. Loboda A., Stachurska A., Dorosz J., Zurawski M., Wegrzyn J., Kozakowska M., Jozkowicz A., Dulak J. HIF-1 attenuates Ref-1 expression in endothelial cells: reversal by siRNA and inhibition of geranylgeranylation. Vascul. Pharmacol. 2009, 51(2-3):133-139. http://www.ncbi.nlm.nih.gov/pubmed/19524065, 10.1016/j.vph.2009.05.005.
118. Hirota K., Murata M., Sachi Y., Nakamura H., Takeuchi J., Mori K., Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J. Biol. Chem. 1999, 274(39):27891-27897. http://www.ncbi.nlm.nih.gov/pubmed/10488136, 10.1074/jbc.274.39.27891.
119. Grösch S., Kaina B. Transcriptional activation of apurinic/apyrimidinic endonuclease (ape, Ref-1) by oxidative stress requires CREB. Biochem. Biophys. Res. Commun. 1999, 261(3):859-863. http://www.ncbi.nlm.nih.gov/pubmed/10441516, 10.1006/bbrc.1999.1125.
120. Walker L.J., Robson C.N., Black E., Gillespie D., Hickson I.D. Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol. Cell. Biol. 1993, 13(9):5370-5376. http://www.ncbi.nlm.nih.gov/pubmed/8355688.
121. Kelley M.R., Parsons S.H. Redox regulation of the DNA repair function of the human AP endonuclease Ape1/ref-1. Antioxid. Redox Signal. 2001, 3(4):671-683. http://www.ncbi.nlm.nih.gov/pubmed/11554453, 10.1089/15230860152543014.
122. Bennett S.M., Neher T.M., Shatilla A., Turchi J.J. Molecular analysis of Ku redox regulation. BMC Mol. Biol. 2009, 10:86. http://www.ncbi.nlm.nih.gov/pubmed/19715578, 10.1186/1471-2199-10-86.
123. Yoo S., Dynan W.S. Geometry of a complex formed by double strand break repair proteins at a single DNA end: recruitment of DNA-PKcs induces inward translocation of Ku protein. Nucleic Acids Res. 1999, 27(24):4679-4686. http://www.ncbi.nlm.nih.gov/pubmed/10572166, 10.1093/nar/27.24.4679.
124. Andrews B.J., Lehman J.A., Turchi J.J. Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex. J. Biol. Chem. 2006, 281(19):13596-13603. http://www.ncbi.nlm.nih.gov/pubmed/16537541, 10.1074/jbc.M512787200.
125. Wei W., Yang Z., Tang C.H., Liu L. Targeted deletion of GSNOR in hepatocytes of mice causes nitrosative inactivation of O6-alkylguanine-DNA alkyltransferase and increased sensitivity to genotoxic diethylnitrosamine. Carcinogenesis 2011, 32(7):973-977. http://www.ncbi.nlm.nih.gov/pubmed/21385828, 10.1093/carcin/bgr041.
126. Cyr A.R., Domann F.E. The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid. Redox Signal. 2011, 15(2):551-589. http://www.ncbi.nlm.nih.gov/pubmed/20919933, 10.1089/ars.2010.3492.
127. A.M. Baird, K.J. O'Byrne, S.G. Gray, Reactive oxygen species and reactive nitrogen species in epigenetic modifications, in: I. Laher (Ed.). Systems Biology of Free Radicals and Antioxidants, Springer-Verlag, Berlin Heidelberg, 2014, pp. 437-455.
128. Hitchler M.J., Domann F.E. Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome. Free Radic. Biol. Med. 2012, 53(11):2178-2187. http://www.ncbi.nlm.nih.gov/pubmed/23022407, 10.1016/j.freeradbiomed.2012.09.028.
129. Kim G.H., Ryan J.J., Archer S.L. The role of redox signaling in epigenetics and cardiovascular disease. Antioxid. Redox Signal. 2013, 18(15):1920-1936. http://www.ncbi.nlm.nih.gov/pubmed/23480168, 10.1089/ars.2012.4926.
130. Heyn H., Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 2012, 13(10):679-692. http://www.ncbi.nlm.nih.gov/pubmed/22945394, 10.1038/nrg3270.
131. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J. Biochem. Mol. Biol. 2003, 36(1):95-109. http://www.ncbi.nlm.nih.gov/pubmed/12542980, 10.5483/BMBRep.2003.36.1.095.
132. Rahman I. Dietary polyphenols mediated regulation of oxidative stress and chromatin remodeling in inflammation. Nutr. Rev. 2008, 66(Suppl. 1):S42-S45. http://www.ncbi.nlm.nih.gov/pubmed/18673489, 10.1111/j.1753-4887.2008.00067.x.
133. Rajendrasozhan S., Yang S.R., Edirisinghe I., Yao H., Adenuga D., Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid. Redox Signal. 2008, 10(4):799-811. http://www.ncbi.nlm.nih.gov/pubmed/18220485, 10.1089/ars.2007.1938.
134. Yang I.A., Relan V., Wright C.M., Davidson M.R., Sriram K.B., Savarimuthu Francis S.M., Clarke B.E., Duhig E.E., Bowman R.V., Fong K.M. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin. Ther. Targets 2011, 15(4):439-456. http://www.ncbi.nlm.nih.gov/pubmed/21284573, 10.1517/14728222.2011.555400.
135. Cheng X., Ku C.H., Siow R.C. Regulation of the Nrf2 antioxidant pathway by microRNAs: new players in micromanaging redox homeostasis. Free Radic. Biol. Med. 2013, 64:4-11. http://www.ncbi.nlm.nih.gov/pubmed/23880293, 10.1016/j.freeradbiomed.2013.07.025.
136. Magenta A., Cencioni C., Fasanaro P., Zaccagnini G., Greco S., Sarra-Ferraris G., Antonini A., Martelli F., Capogrossi M.C. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011, 18(10):1628-1639. http://www.ncbi.nlm.nih.gov/pubmed/21527937, 10.1038/cdd.2011.42.
137. Mateescu B., Batista L., Cardon M., Gruosso T., de Feraudy Y., Mariani O., Nicolas A., Meyniel J.P., Cottu P., Sastre-Garau X., Mechta-Grigoriou F. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 2011, 17(12):1627-1635. http://www.ncbi.nlm.nih.gov/pubmed/22101765, 10.1038/nm.2512.
138. O'Byrne K.J., Barr M.P., Gray S.G. The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers (Basel) 2011, 3(1):1426-1453. http://www.ncbi.nlm.nih.gov/pubmed/24212667, 10.3390/cancers3011426.
139. Thulasingam S., Massilamany C., Gangaplara A., Dai H., Yarbaeva S., Subramaniam S., Riethoven J.J., Eudy J., Lou M., Reddy J. miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells. Mol. Cell. Biochem. 2011, 352(1-2):181-188. http://www.ncbi.nlm.nih.gov/pubmed/21350856, 10.1007/s11010-011-0752-2.
140. Espinosa-Diez C., Fierro-Fernández M., Sánchez-Gómez F., Rodríguez-Pascual F., Alique M., Ruiz-Ortega M., Beraza N., Martínez-Chantar M.L., Fernández-Hernando C., Lamas S. Targeting of gamma-glutamyl-cysteine ligase by miR-433 reduces glutathione biosynthesis and promotes TGF-beta-dependent fibrogenesis. Antioxid. Redox Signal. 2014, 10.1089/ars.2014.6025.
141. Hayes P., Knaus U.G. Balancing reactive oxygen species in the epigenome: NADPH oxidases as target and perpetrator. Antioxid. Redox Signal. 2013, 18(15):1937-1945. http://www.ncbi.nlm.nih.gov/pubmed/23126619, 10.1089/ars.2012.4895.
142. Kang K.A., Zhang R., Kim G.Y., Bae S.C., Hyun J.W. Epigenetic changes induced by oxidative stress in colorectal cancer cells: methylation of tumor suppressor RUNX3. Tumour Biol. 2012, 33(2):403-412. http://www.ncbi.nlm.nih.gov/pubmed/22274925, 10.1007/s13277-012-0322-6.
143. Sanders Y.Y., Liu H., Liu G., Thannickal V.J. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic. Biol. Med. 2015, 79:197-205. http://www.ncbi.nlm.nih.gov/pubmed/25526894, 10.1016/j.freeradbiomed.2014.12.008.
144. Lim S.O., Gu J.M., Kim M.S., Kim H.S., Park Y.N., Park C.K., Cho J.W., Park Y.M., Jung G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 2008, 135(6):2128-2140. http://www.ncbi.nlm.nih.gov/pubmed/18801366, 10.1053/j.gastro.2008.07.027.
145. Hong J., Resnick M., Behar J., Wang L.J., Wands J., DeLellis R.A., Souza R.F., Spechler S.J., Cao W. Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299(3):G697-G706. http://www.ncbi.nlm.nih.gov/pubmed/20576920, 10.1152/ajpgi.00186.2010.
146. Bartling T.R., Subbaram S., Clark R.R., Chandrasekaran A., Kar S., Melendez J.A. Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression. Free Radic. Biol. Med. 2014, 74:99-107. http://www.ncbi.nlm.nih.gov/pubmed/24973648, 10.1016/j.freeradbiomed.2014.06.017.
147. Case A.J., Madsen J.M., Motto D.G., Meyerholz D.K., Domann F.E. Manganese superoxide dismutase depletion in murine hematopoietic stem cells perturbs iron homeostasis, globin switching, and epigenetic control in erythrocyte precursor cells. Free Radic. Biol. Med. 2013, 56:17-27. http://www.ncbi.nlm.nih.gov/pubmed/23219873, 10.1016/j.freeradbiomed.2012.11.018.
148. Wang X., Vatamaniuk M.Z., Roneker C.A., Pepper M.P., Hu L.G., Simmons R.A., Lei X.G. Knockouts of SOD1 and GPX1 exert different impacts on murine islet function and pancreatic integrity. Antioxid. Redox Signal. 2011, 14(3):391-401. http://www.ncbi.nlm.nih.gov/pubmed/20586612, 10.1089/ars.2010.3302.
149. Verdin E., Ott M. 50 Years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell Biol. 2015, 16(4):258-264. http://www.ncbi.nlm.nih.gov/pubmed/25549891, 10.1038/nrm3931.
150. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13(9):673-691. http://www.ncbi.nlm.nih.gov/pubmed/25131830, 10.1038/nrd4360.
151. Radak Z., Koltai E., Taylor A.W., Higuchi M., Kumagai S., Ohno H., Goto S., Boldogh I. Redox-regulating sirtuins in aging, caloric restriction, and exercise. Free Radic. Biol. Med. 2013, 58:87-97. http://www.ncbi.nlm.nih.gov/pubmed/23339850, 10.1016/j.freeradbiomed.2013.01.004.
152. Escobar J., Pereda J., López-Rodas G., Sastre J. Redox signaling and histone acetylation in acute pancreatitis. Free Radic. Biol. Med. 2012, 52(5):819-837. http://www.ncbi.nlm.nih.gov/pubmed/22178977, 10.1016/j.freeradbiomed.2011.11.009.
153. Zee R.S., Yoo C.B., Pimentel D.R., Perlman D.H., Burgoyne J.R., Hou X., McComb M.E., Costello C.E., Cohen R.A., Bachschmid M.M. Redox regulation of sirtuin-1 by S-glutathiolation. Antioxid. Redox Signal. 2010, 13(7):1023-1032. http://www.ncbi.nlm.nih.gov/pubmed/20392170, 10.1089/ars.2010.3251.
154. Bräutigam L., Jensen L.D., Poschmann G., Nyström S., Bannenberg S., Dreij K., Lepka K., Prozorovski T., Montano S.J., Aktas O., Uhlén P., Stühler K., Cao Y., Holmgren A., Berndt C. Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1. Proc. Natl. Acad. Sci. USA 2013, 110(50):20057-20062. http://www.ncbi.nlm.nih.gov/pubmed/24277839, 10.1073/pnas.1313753110.
155. Shao D., Fry J.L., Han J., Hou X., Pimentel D.R., Matsui R., Cohen R.A., Bachschmid M.M. A redox-resistant sirtuin-1 mutant protects against hepatic metabolic and oxidant stress. J. Biol. Chem. 2014, 289(11):7293-7306. http://www.ncbi.nlm.nih.gov/pubmed/24451382, 10.1074/jbc.M113.520403.
156. Caito S., Rajendrasozhan S., Cook S., Chung S., Yao H., Friedman A.E., Brookes P.S., Rahman I. SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J. 2010, 24(9):3145-3159. http://www.ncbi.nlm.nih.gov/pubmed/20385619, 10.1096/fj.09-151308.
157. Doyle K., Fitzpatrick F.A. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J. Biol. Chem. 2010, 285(23):17417-17424. http://www.ncbi.nlm.nih.gov/pubmed/20385560, 10.1074/jbc.M109.089250.
158. Fritz K.S., Galligan J.J., Smathers R.L., Roede J.R., Shearn C.T., Reigan P., Petersen D.R. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem. Res. Toxicol. 2011, 24(5):651-662. http://www.ncbi.nlm.nih.gov/pubmed/21449565, 10.1021/tx100355a.
159. Vatsyayan R., Kothari H., Pendurthi U.R., Rao L.V. 4-Hydroxy-2-nonenal enhances tissue factor activity in human monocytic cells via p38 mitogen-activated protein kinase activation-dependent phosphatidylserine exposure. Arterioscler. Thromb. Vasc. Biol. 2013, 33(7):1601-1611. http://www.ncbi.nlm.nih.gov/pubmed/23640483, 10.1161/ATVBAHA.113.300972.
160. Monfort A., Wutz A. Breathing-in epigenetic change with vitamin C. EMBO Rep. 2013, 14(4):337-346. http://www.ncbi.nlm.nih.gov/pubmed/23492828, 10.1038/embor.2013.29.
161. Wang T., Chen K., Zeng X., Yang J., Wu Y., Shi X., Qin B., Zeng L., Esteban M.A., Pan G., Pei D. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell 2011, 9(6):575-587. http://www.ncbi.nlm.nih.gov/pubmed/22100412, 10.1016/j.stem.2011.10.005.
162. Chervona Y., Costa M. The control of histone methylation and gene expression by oxidative stress, hypoxia, and metals. Free Radic. Biol. Med. 2012, 53(5):1041-1047. http://www.ncbi.nlm.nih.gov/pubmed/22841757, 10.1016/j.freeradbiomed.2012.07.020.
163. Polytarchou C., Pfau R., Hatziapostolou M., Tsichlis P.N. The JmjC domain histone demethylase Ndy1 regulates redox homeostasis and protects cells from oxidative stress. Mol. Cell. Biol. 2008, 28(24):7451-7464. http://www.ncbi.nlm.nih.gov/pubmed/18838535, 10.1128/MCB.00688-08.
164. Li J., Braganza A., Sobol R.W. Base excision repair facilitates a functional relationship between guanine oxidation and histone demethylation. Antioxid. Redox Signal. 2013, 18(18):2429-2443. http://www.ncbi.nlm.nih.gov/pubmed/23311711, 10.1089/ars.2012.5107.
165. Perillo B., Ombra M.N., Bertoni A., Cuozzo C., Sacchetti S., Sasso A., Chiariotti L., Malorni A., Abbondanza C., Avvedimento E.V. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008, 319(5860):202-206. http://www.ncbi.nlm.nih.gov/pubmed/18187655, 10.1126/science.1147674.
166. Chia N., Wang L., Lu X., Senut M.C., Brenner C., Ruden D.M. Hypothesis: environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics 2011, 6(7):853-856. http://www.ncbi.nlm.nih.gov/pubmed/21617369, 10.4161/epi.6.7.16461.
167. Valinluck V., Tsai H.H., Rogstad D.K., Burdzy A., Bird A., Sowers L.C. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004, 32(14):4100-4108. http://www.ncbi.nlm.nih.gov/pubmed/15302911, 10.1093/nar/gkh739.
168. Valinluck V., Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007, 67(3):946-950. http://www.ncbi.nlm.nih.gov/pubmed/17283125, 10.1158/0008-5472.CAN-06-3123.
169. Valinluck V., Sowers L.C. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 2007, 67(12):5583-5586. http://www.ncbi.nlm.nih.gov/pubmed/17575120, 10.1158/0008-5472.CAN-07-0846.
170. Lao V.V., Herring J.L., Kim C.H., Darwanto A., Soto U., Sowers L.C. Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns. Carcinogenesis 2009, 30(5):886-893. http://www.ncbi.nlm.nih.gov/pubmed/19279184, 10.1093/carcin/bgp060.
171. Azad N., Zahnow C.A., Rudin C.M., Baylin S.B. The future of epigenetic therapy in solid tumours - lessons from the past. Nat. Rev. Clin. Oncol. 2013, 10(5):256-266. http://www.ncbi.nlm.nih.gov/pubmed/23546521, 10.1038/nrclinonc.2013.42.
172. Lupo B., Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim. Biophys. Acta 2014, 1846(1):201-215. http://www.ncbi.nlm.nih.gov/pubmed/25026313, 10.1016/j.bbcan.2014.07.004.
173. Curtin N.J. PARP inhibitors for cancer therapy. Expert Rev. Mol. Med. 2005, 7(04):1-20. 10.1017/S146239940500904X.
174. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Massé A., Kosmider O., Le Couedic J.P., Robert F., Alberdi A., Lécluse Y., Plo I., Dreyfus F.J., Marzac C., Casadevall N., Lacombe C., Romana S.P., Dessen P., Soulier J., Viguié F., Fontenay M., Vainchenker W., Bernard O.A. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360(22):2289-2301. http://www.ncbi.nlm.nih.gov/pubmed/19474426, 10.1056/NEJMoa0810069.
175. Kantarjian H.M., Thomas X.G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., Gau J.P., Chou W.C., Buckstein R., Cermak J., Kuo C.Y., Oriol A., Ravandi F., Faderl S., Delaunay J., Lysak D., Minden M., Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 2012, 30(21):2670-2677. 10.1200/JCO.2011.38.9429.
176. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., Schoch R., Gattermann N., Sanz G., List A., Gore S.D., Seymour J.F., Bennett J.M., Byrd J., Backstrom J., Zimmerman L., McKenzie D., Beach C., Silverman L.R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10(3):223-232. International Vidaza High-Risk MDS Survival Study Group. http://www.ncbi.nlm.nih.gov/pubmed/19230772, 10.1016/S1470-2045(09)70003-8.
177. Nass N., Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol. Res. Pract. 2015, 211(3):189-197. http://www.ncbi.nlm.nih.gov/pubmed/25666016, 10.1016/j.prp.2015.01.004.
178. Olm E., Jönsson-Videsäter K., Ribera-Cortada I., Fernandes A.P., Eriksson L.C., Lehmann S., Rundlöf A.K., Paul C., Björnstedt M. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett. 2009, 282(1):116-123. http://www.ncbi.nlm.nih.gov/pubmed/19345479, 10.1016/j.canlet.2009.03.010.
179. Goto S., Kamada K., Soh Y., Ihara Y., Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn. J. Cancer Res. 2002, 93(9):1047-1056. http://www.ncbi.nlm.nih.gov/pubmed/12359059, 10.1111/j.1349-7006.2002.tb02482.x.
180. Cyr A.R., Hitchler M.J., Domann F.E. Regulation of SOD2 in cancer by histone modifications and CpG methylation: closing the loop between redox biology and epigenetics. Antioxid. Redox Signal. 2013, 18(15):1946-1955. http://www.ncbi.nlm.nih.gov/pubmed/22946823, 10.1089/ars.2012.4850.
181. Wang R., An J., Ji F., Jiao H., Sun H., Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun. 2008, 373(1):151-154. http://www.ncbi.nlm.nih.gov/pubmed/18555005, 10.1016/j.bbrc.2008.06.004.
182. Archer S.L., Marsboom G., Kim G.H., Zhang H.J., Toth P.T., Svensson E.C., Dyck J.R., Gomberg-Maitland M., Thébaud B., Husain A.N., Cipriani N., Rehman J. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010, 121(24):2661-2671. http://www.ncbi.nlm.nih.gov/pubmed/20529999, 10.1161/CIRCULATIONAHA.109.916098.
183. Kamiya T., Machiura M., Makino J., Hara H., Hozumi I., Adachi T. Epigenetic regulation of extracellular-superoxide dismutase in human monocytes. Free Radic. Biol. Med. 2013, 61:197-205. http://www.ncbi.nlm.nih.gov/pubmed/23602908, 10.1016/j.freeradbiomed.2013.04.013.
184. Zelko I.N., Folz R.J. Regulation of Oxidative Stress in Pulmonary Artery Endothelium: modulation of EC-SOD and NOX4 expression using HDAC Class I. Inhibitors. Am. J. Respir. Cell Mol. Biol. 2015, 10.1165/rcmb.2014-0260OC.
185. Teoh-Fitzgerald M.L., Fitzgerald M.P., Zhong W., Askeland R.W., Domann F.E. Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis. Oncogene 2014, 33(3):358-368. http://www.ncbi.nlm.nih.gov/pubmed/23318435, 10.1038/onc.2012.582.
186. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., Barnes P.J. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA 2002, 99(13):8921-8926. http://www.ncbi.nlm.nih.gov/pubmed/12070353, 10.1073/pnas.132556899.
187. Ford P.A., Durham A.L., Russell R.E., Gordon F., Adcock I.M., Barnes P.J. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010, 137(6):1338-1344. http://www.ncbi.nlm.nih.gov/pubmed/20299628, 10.1378/chest.09-2363.
188. Mukhopadhyay P., Pacher P., Das D.K. MicroRNA signatures of resveratrol in the ischemic heart. Ann. N. Y. Acad. Sci. 2011, 1215:109-116. http://www.ncbi.nlm.nih.gov/pubmed/21261648, 10.1111/j.1749-6632.2010.05866.x.
189. Farghali H., Kutinová Canová N., Lekić N. Resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol. Res. 2013, 62(1):1-13. http://www.ncbi.nlm.nih.gov/pubmed/23173686.
190. Xia N., Forstermann U., Li H. Resveratrol as a gene regulator in the vasculature. Curr. Pharm. Biotechnol. 2014, 15(4):401-408. http://www.ncbi.nlm.nih.gov/pubmed/25022271, 10.2174/1389201015666140711114450.
191. Gatz S.A., Wiesmüller L. Take a break - resveratrol in action on DNA. Carcinogenesis 2008, 29(2):321-332. http://www.ncbi.nlm.nih.gov/pubmed/18174251, 10.1093/carcin/bgm276.
192. Malireddy S., Kotha S.R., Secor J.D., Gurney T.O., Abbott J.L., Maulik G., Maddipati K.R., Parinandi N.L. Phytochemical antioxidants modulate mammalian cellular epigenome: implications in health and disease. Antioxid. Redox Signal. 2012, 17(2):327-339. http://www.ncbi.nlm.nih.gov/pubmed/22404530, 10.1089/ars.2012.4600.
193. Kodach L.L., Jacobs R.J., Voorneveld P.W., Wildenberg M.E., Verspaget H.W., van Wezel T., Morreau H., Hommes D.W., Peppelenbosch M.P., van den Brink G.R., Hardwick J.C. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011, 60(11):1544-1553. http://www.ncbi.nlm.nih.gov/pubmed/21551187, 10.1136/gut.2011.237495.
194. Ishikawa S., Hayashi H., Kinoshita K., Abe M., Kuroki H., Tokunaga R., Tomiyasu S., Tanaka H., Sugita H., Arita T., Yagi Y., Watanabe M., Hirota M., Baba H. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int. J. Cancer 2014, 135(11):2528-2536. http://www.ncbi.nlm.nih.gov/pubmed/24346863, 10.1002/ijc.28672.
195. Tikoo K., Patel G., Kumar S., Karpe P.A., Sanghavi M., Malek V., Srinivasan K. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem. Pharmacol. 2015, 93(3):343-351. http://www.ncbi.nlm.nih.gov/pubmed/25482567, 10.1016/j.bcp.2014.11.013.
196. Münzel T., Daiber A., Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011, 123(19):2132-2144. http://www.ncbi.nlm.nih.gov/pubmed/21576678, 10.1161/CIRCULATIONAHA.110.981407.
197. Schuhmacher S., Wenzel P., Schulz E., Oelze M., Mang C., Kamuf J., Gori T., Jansen T., Knorr M., Karbach S., Hortmann M., Mäthner F., Bhatnagar A., Förstermann U., Li H., Münzel T., Daiber A. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 2010, 55(4):897-904. http://www.ncbi.nlm.nih.gov/pubmed/20157049, 10.1161/HYPERTENSIONAHA.109.149542.
198. Schuhmacher S., Oelze M., Bollmann F., Kleinert H., Otto C., Heeren T., Steven S., Hausding M., Knorr M., Pautz A., Reifenberg K., Schulz E., Gori T., Wenzel P., Münzel T., Daiber A. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011, 60(10):2608-2616. http://www.ncbi.nlm.nih.gov/pubmed/21844097, 10.2337/db10-1395.
199. Pautz A., Rauschkolb P., Schmidt N., Art J., Oelze M., Wenzel P., Förstermann U., Daiber A., Kleinert H. Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol. Genomics 2009, 38(2):176-185. http://www.ncbi.nlm.nih.gov/pubmed/19417013, 10.1152/physiolgenomics.00035.2009.
200. Wu Z., Siuda D., Xia N., Reifenberg G., Daiber A., Münzel T., Förstermann U., Li H. Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring. Hypertension 2015, 65(1):232-237. http://www.ncbi.nlm.nih.gov/pubmed/25385760, 10.1161/HYPERTENSIONAHA.114.04416.
201. Colussi C., Scopece A., Vitale S., Spallotta F., Mattiussi S., Rosati J., Illi B., Mai A., Castellano S., Sbardella G., Farsetti A., Capogrossi M.C., Gaetano C. P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N{varepsilon}-lysine acetylation of contractile proteins. Arterioscler. Thromb. Vasc. Biol. 2012, 32(10):2435-2443. http://www.ncbi.nlm.nih.gov/pubmed/22859492, 10.1161/ATVBAHA.112.254011.
202. Lawless M.W., O'Byrne K.J., Gray S.G. Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J. Cell. Mol. Med. 2009, 13(9A):2800-2821. http://www.ncbi.nlm.nih.gov/pubmed/19602054, 10.1111/j.1582-4934.2009.00845.x.